5-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot study
Purpose: The surgical technique of periglandular 5-fluorouracil (5-FU) injection and its effects on the morphology and function of the main lacrimal gland of patients with severe dry eye disease due to Stevens–Johnson syndrome (SJS) are reported. Methods: 5-FU, as a potential antifibrotic agent, is...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=4;spage=1626;epage=1629;aulast=Singh |
| _version_ | 1797824308616101888 |
|---|---|
| author | Swati Singh Sayan Basu |
| author_facet | Swati Singh Sayan Basu |
| author_sort | Swati Singh |
| collection | DOAJ |
| description | Purpose: The surgical technique of periglandular 5-fluorouracil (5-FU) injection and its effects on the morphology and function of the main lacrimal gland of patients with severe dry eye disease due to Stevens–Johnson syndrome (SJS) are reported. Methods: 5-FU, as a potential antifibrotic agent, is given in the dose of 0.1 ml (50 mg/ml), subconjunctivally into the periglandular fibrosed area of the palpebral lobe of the main lacrimal gland. The injection is given using 30G needle into the subconjunctival plane and not into the substance of palpebral lobe. Results: Eight eyes (eight lobes) of seven chronic SJS patients (mean age, 32.5 years, <5 mm Schirmer) received the injection. All eight lobes demonstrated a visible reduction in the conjunctival congestion and scarring over the lobar area. The mean OSDI scoring improved from 65.3 to 51.1. Three patients with mean pre-injection Schirmer I values of 4 mm showed a mean change of 1 mm at four weeks following a single injection. The tear flow rate per lobe for the above three patients improved from 0.22, 0.12, and 0.16 μl/min to 0.31, 0.12, and 0.21 μl/min, respectively. Another patient with pre-injection Schirmer of 4 mm showed no change in tear flow. Three eyes with zero baseline Schirmer values (no visible secretory opening) had no improvement in tearing or ocular surface staining. Conclusion: Local 5-FU injection alters morphology of the conjunctiva overlying the palpebral lobe in SJS patients, but fails to show any significant effect on tear secretion. |
| first_indexed | 2024-03-13T10:37:05Z |
| format | Article |
| id | doaj.art-6e42a12081b14cbcaac5b83ad9d90361 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-03-13T10:37:05Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-6e42a12081b14cbcaac5b83ad9d903612023-05-18T05:50:42ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892023-01-017141626162910.4103/IJO.IJO_2647_225-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot studySwati SinghSayan BasuPurpose: The surgical technique of periglandular 5-fluorouracil (5-FU) injection and its effects on the morphology and function of the main lacrimal gland of patients with severe dry eye disease due to Stevens–Johnson syndrome (SJS) are reported. Methods: 5-FU, as a potential antifibrotic agent, is given in the dose of 0.1 ml (50 mg/ml), subconjunctivally into the periglandular fibrosed area of the palpebral lobe of the main lacrimal gland. The injection is given using 30G needle into the subconjunctival plane and not into the substance of palpebral lobe. Results: Eight eyes (eight lobes) of seven chronic SJS patients (mean age, 32.5 years, <5 mm Schirmer) received the injection. All eight lobes demonstrated a visible reduction in the conjunctival congestion and scarring over the lobar area. The mean OSDI scoring improved from 65.3 to 51.1. Three patients with mean pre-injection Schirmer I values of 4 mm showed a mean change of 1 mm at four weeks following a single injection. The tear flow rate per lobe for the above three patients improved from 0.22, 0.12, and 0.16 μl/min to 0.31, 0.12, and 0.21 μl/min, respectively. Another patient with pre-injection Schirmer of 4 mm showed no change in tear flow. Three eyes with zero baseline Schirmer values (no visible secretory opening) had no improvement in tearing or ocular surface staining. Conclusion: Local 5-FU injection alters morphology of the conjunctiva overlying the palpebral lobe in SJS patients, but fails to show any significant effect on tear secretion.http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=4;spage=1626;epage=1629;aulast=Singh5-fluorouracillacrimal glandpalpebral lobestevens–johnson syndrometears |
| spellingShingle | Swati Singh Sayan Basu 5-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot study Indian Journal of Ophthalmology 5-fluorouracil lacrimal gland palpebral lobe stevens–johnson syndrome tears |
| title | 5-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot study |
| title_full | 5-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot study |
| title_fullStr | 5-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot study |
| title_full_unstemmed | 5-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot study |
| title_short | 5-Fluorouracil as a targeted lacrimal gland therapy for chronic Stevens-Johnson syndrome: A pilot study |
| title_sort | 5 fluorouracil as a targeted lacrimal gland therapy for chronic stevens johnson syndrome a pilot study |
| topic | 5-fluorouracil lacrimal gland palpebral lobe stevens–johnson syndrome tears |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=4;spage=1626;epage=1629;aulast=Singh |
| work_keys_str_mv | AT swatisingh 5fluorouracilasatargetedlacrimalglandtherapyforchronicstevensjohnsonsyndromeapilotstudy AT sayanbasu 5fluorouracilasatargetedlacrimalglandtherapyforchronicstevensjohnsonsyndromeapilotstudy |